Sanofi Consumer Healthcare India Ltd Q4 FY26 Results

Summary

Sanofi Consumer Healthcare India Limited demonstrated strong financial performance in Q1 FY26, with revenue climbing 33% year-on-year to ₹2,292 million. Profit after tax also saw a robust increase of 36% to ₹678 million during the quarter. This growth was notably supported by a 15.5% rise in domestic sales, aided by product relaunches, and an impressive 144% surge in export sales from a low base. Himanshu Bakshi, Managing Director, emphasized consistent execution, noting that the domestic business outperformed the market in both share and volume, while exports made a meaningful contribution. The company remains committed to simplifying self-care and enhancing accessibility for consumers.

Key Highlights

1. 1

   Sanofi Consumer Healthcare India Limited reported Q1 FY26 revenue of ₹2,292 million, marking a substantial 33% growth year-on-year.

2. 2

   Profit After Tax (PAT) for the quarter increased by 36% year-on-year, reaching ₹678 million.

3. 3

   Domestic sales for Q1 FY26 grew by 15.5%, primarily driven by the relaunch of recalled products to the market.

4. 4

   Export sales saw a significant surge of 144% during the quarter, attributed to a low base in the comparable period.

5. 5

   Managing Director Himanshu Bakshi noted that the domestic business outpaced the market, achieving both market share gains and volume growth.